Education
About Us
Working with TipRanks
Follow Us
Sellas Life Sciences Group (SLS)
:SLS
Total Valuation
SELLAS Life Sciences Group has a market cap or net worth of $259.24M. The enterprise value is $130.70M.
Market Cap$259.24M
Enterprise Value$130.70M
Share Statistics
SELLAS Life Sciences Group has 142,442,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding142,442,250
Owned by Insiders1.28%
Owned by Institutions7.79%
Financial Efficiency
SELLAS Life Sciences Group’s return on equity (ROE) is -3.26 and return on invested capital (ROIC) is -286.22%.
Return on Equity (ROE)-3.26
Return on Assets (ROA)-1.59
Return on Invested Capital (ROIC)-286.22%
Return on Capital Employed (ROCE)-3.18
Revenue Per Employee0.00
Profits Per Employee-2.06M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of SELLAS Life Sciences Group is ―. SELLAS Life Sciences Group’s PEG ratio is 0.31.
PE Ratio―
PS Ratio0.00
PB Ratio67.25
Price to Fair Value67.25
Price to FCF-17.98
Price to Operating Cash Flow-4.43
PEG Ratio0.31
Income Statement
In the last 12 months, SELLAS Life Sciences Group had revenue of 0.00 and earned -30.88M in profits. Earnings per share was -0.05.
Revenue0.00
Gross Profit0.00
Operating Income-31.51M
Pretax Income-30.88M
Net Income-30.88M
EBITDA632.00K
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -30.62M and capital expenditures 0.00, giving a free cash flow of -30.62M billion.
Operating Cash Flow-30.62M
Free Cash Flow-30.62M
Free Cash Flow per Share-0.21
Dividends & Yields
SELLAS Life Sciences Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.99
52-Week Price Change111.11%
50-Day Moving Average1.75
200-Day Moving Average1.62
Relative Strength Index (RSI)61.95
Average Volume (3m)4.05M
Important Dates
SELLAS Life Sciences Group upcoming earnings date is Mar 13, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 13, 2026
Ex-Dividend Date―
Financial Position
SELLAS Life Sciences Group as a current ratio of 1.72, with Debt / Equity ratio of 2.82%
Current Ratio1.72
Quick Ratio1.72
Debt to Market Cap<0.01
Net Debt to EBITDA0.42
Interest Coverage Ratio0.00
Taxes
In the past 12 months, SELLAS Life Sciences Group has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
SELLAS Life Sciences Group EV to EBITDA ratio is -20.19, with an EV/FCF ratio of -17.61.
EV to Sales0.00
EV to EBITDA-20.19
EV to Free Cash Flow-17.61
EV to Operating Cash Flow-17.61
Balance Sheet
SELLAS Life Sciences Group has $44.42M in cash and marketable securities with $599.00K in debt, giving a net cash position of $43.82M billion.
Cash & Marketable Securities$44.42M
Total Debt$599.00K
Net Cash$43.82M
Net Cash Per Share$0.31
Tangible Book Value Per Share$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for SELLAS Life Sciences Group is $7.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.25
Price Target Upside279.58% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast59.04%